MYGN - ミリアド・ジェネティックス (Myriad Genetics Inc.) ミリアド・ジェネティックス

 MYGNのチャート


 MYGNの企業情報

symbol MYGN
会社名 Myriad Genetics Inc. (ミリアド・ジェネティックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: In Vitro_In Vivo Diagnostic Substances  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 ミリアド・ジェネティクス(Myriad Genetics Inc.)は分子診断会社である。同社は形質転換的分子診断検査の発見、開発、販売に従事する。同社は、診断およびその他の2つの区分を通じて事業を行う。診断セグメントは病気を発症するリスクを評価し、薬物療法に応答する患者の可能性を特定し、最適な治療を可能にするために患者の投薬を導き、患者のリスクを評価するためのテストの共同開発を提供する。その他のセグメントは、医薬品バイオテクノロジー、医療研究業界、研究開発および患者の臨床サービスに試験製品およびサービスを提供し、金融、人材、法律および情報技術などの企業サービスも含む。その分子診断検査には、myRisk遺伝性がん、BRACAnalysis CDxおよびCOLARISが含まれる。   ミリアド・ジェネティックスは、米国のバイオ医薬品企業。P4医療に焦点を置いた医薬品と分子診断製品を扱う。主要製品は遺伝性乳がんと卵巣がんの易罹患性の遺伝子検査「BRACAnalysis」、結腸直がんと子宮がんの遺伝子検査「Colaris」、メラノ―マ遺伝子検査「Melaris」、遺伝性膵臓がん発症予測検査「PANEXIA」など。   Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.
本社所在地 320 Wakara Way Salt Lake City UT 84108 USA
代表者氏名 John T. Henderson ジョン・T・ヘンダーソン
代表者役職名 Independent Chairman of the Board
電話番号 +1 801-584-3600
設立年月日 33359
市場名 NASDAQ National Market System
ipoyear 1995年
従業員数 2400人
url www.myriad.com
nasdaq_url https://www.nasdaq.com/symbol/mygn
adr_tso
EBITDA EBITDA(百万ドル) 172.90000
終値(lastsale) 43.02
時価総額(marketcap) 3050993629.08
時価総額 時価総額(百万ドル) 3264.328
売上高 売上高(百万ドル) 772.60000
企業価値(EV) 企業価値(EV)(百万ドル) 393.028
当期純利益 当期純利益(百万ドル) 96.70000
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Myriad Genetics Inc. revenues increased less than 1% to $772.6M. Net income before extraordinary items increased from $21.8M to $99.1M. Revenues reflect Other segment increase of 8% to $53.3M also reflect Diagnostics segment decrease of less than 1% to $719.3M. Net income benefited from Other segment loss decrease of 74% to $20.7M Diagnostics segment income increase of 8% to $139.4M.

 MYGNのテクニカル分析


 MYGNのニュース

   The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes  2021/03/17 11:43:07 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 16) Affimed N.V. (NASDAQ: AFMD ) BioAtla, Inc. (NASDAQ: BCAB ) Champions Oncology, Inc. (NASDAQ: CSBR ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Omnicell, Inc. (NASDAQ: OMCL ) Savara Inc. (NASDAQ: SVRA ) (reacted to a positive analyst action and insider buying) Sierra Oncology, Inc. (NASDAQ: SRRA ) Sol-Gel Technologies Ltd. (NASDAQ: SLGL ) Vincerx Pharma, Inc. (NASDAQ: VINC ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 16) Galecto, Inc. (NASDAQ: GLTO ) Immunocore Holdings plc (NASDAQ: IMCR ) Stocks In Focus Pfizer to Sell Chinese Biologics Unit to WuXi Pfizer Inc.'s (NYSE: PFE ) China unit and Hong Kong-listed WuXi Biologics announced an equity agreement under which the latter will acquire the former's state-of-the-art biologics manufacturing facilities as well as its labor force in Hangzhou, China.
   Cancer Biomarkers Market US$ 31,206.00 Mn in 2027 with QIAGEN, bioMérieux, Inc., Creative Diagnostics, Hologic Inc., Quest Diagnostics, Myriad Genetics, Inc.  2021/03/02 13:28:32 OpenPR
Cancer Biomarkers Market research report delivers a comprehensive study on production capacity, consumption, import and export for all major regions across the world. Report provides is a professional inclusive study on the current state for the market. Analysis and discussion
   The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida  2021/02/26 13:16:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25) Apyx Medical Corp (NASDAQ: APYX ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (announced an $18-million private placement) Bioatla Inc (NASDAQ: BCAB ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Glaukos Corp (NYSE: GKOS ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pacira Biosciences Inc (NASDAQ: PCRX ) (announced fourth-quarter results) Pandion Therapeutics Inc (NASDAQ: PAND ) - announced a deal to be bought by Merck & Co., Inc. (NYSE: MRK ) for $1.85 billion Pliant Therapeutics Inc (NASDAQ: PLRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 25) Acutus Medical Inc (NASDAQ: AFIB ) Aptose Biosciences Inc (NASDAQ: APTO ) Bioventus Class A Ord Shs (Proposed) (NASDAQ: BVS ) Epizyme Inc (NASDAQ: EPZM ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) (reacted to fourth-quarter results) Lucira Health Inc (NASDAQ: LHDX ) Opthea Spon American Depositary Receipts Representing 8 Ord Shs (NASDAQ: OPT ) Sensei Biotherapeutics Inc (NASDAQ: SNSE ) Virios Therapeutics LLC (NASDAQ: VIR ) Voyager Therapeutics Inc (NASDAQ: VYGR ) Stocks In Focus Tricida Receives Appeals Denied Letter From FDA Regarding Veverimer Tricida Inc (NASDAQ: TCDA ) said it has received an appeal denied letter, or ADL, from the FDA's Office of New Drugs in response to a formal dispute resolution request submitted in December regarding its NDA for veverimer, which is being evaluated as a treatment option for metabolic acidosis in chronic kidney disease patients.
   Cancer Biomarkers Market to Set Phenomenal Growth from 2021 to 2026| Becton, Agilent Technologies, Biomerieux, Myriad Genetics  2021/02/23 13:00:26 OpenPR
Global Cancer Biomarkers Market Report 2021 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers,
   Myriad Genetics Analysts Are Pretty Bullish ... Stock market Insights & financial analysis  2021/02/22 17:30:00 Stock Market Daily
Myriad Genetics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs  2021/02/04 12:21:57 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 3) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Arcus Biosciences Inc (NYSE: RCUS ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) BioVie Inc (NASDAQ: BIVI ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cassava Sciences Inc (NASDAQ: SAVA ) Castle Biosciences Inc (NASDAQ: CSTL ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) CorMedix Inc. Common Stock (NASDAQ: CRMD ) F-Star Therapeutics Inc (NASDAQ: FSTX ) Frequency Therapeutics Inc (NASDAQ: FREQ ) Glaukos Corp (NYSE: GKOS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) ( announced a deal to be bought by Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) for $7.2 billion) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) I-Mab ADR (NASDAQ: IMAB ) Immunome Inc (NASDAQ: IMNM ) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) Jounce Therapeutics Inc (NASDAQ: JNCE ) MannKind Corporation (NASDAQ: MNKD ) Morphic Holding Inc (NASDAQ: MORF ) Myriad Genetics, Inc.
   Myriad Genetics Launches New Vectra® Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis  2021/02/02 12:05:00 Yahoo Finance
Sample test report for Vectra CV. Sample test report for Vectra CV. SALT LAKE CITY, Feb. 02, 2021 (GLOBE NEWSWIRE) -- To help more patients with rheumatoid arthritis (RA), Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today launched the new Vectra® Cardiovascular Risk assessment that can predict the risk for cardiovascular (CV) events in patients with RA. This new test result incorporates information on RA inflammation assessed by Vectra Score and three additional biomarkers, combined with traditional risk factors. Vectra is an advanced blood test that objectively measures inflammation caused by RA. “Due to inflammatory processes, patients with RA have approximately 50% greater risk for cardiovascular disease (CVD), the leading cause of mortality among patients with RA, which accounts for 30-40% of deaths.” said Elena Hitraya, M.D., Ph.D., rheumatologist and chief medical officer with Myriad Autoimmune. “The newly developed Multi-Biomarker Based CVD Risk Score (Vectra Cardiovascular Risk) can accurately predict the risk of major CV events over the next three years, both overall and in important subgroups of patients with RA.
   Liquid Biopsy Market Size, Outlook, Opportunities and Forecasts Report 2020-2027 | Biocept, Inc., Qiagen, F. Hoffmann-La Roche AG, Bio-Rad Laboratories Inc., Myriad Genetics, Janssen Diagnostics, LLC  2021/01/15 10:56:17 OpenPR
Global Liquid Biopsy Market research report provides an in-depth analysis of the industry and economy-wide database for the business management that could potentially offer development and profitability for players in this market. The Liquid Biopsy Market report discusses all major
   Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling  2021/01/11 19:05:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--With genetic sequencing at the forefront of precision medicine, Illumina (NASDAQ: ILMN) is pleased to announce a portfolio of new and expanded oncology partnerships that further the company’s commitment to develop standardized, globally distributable tools for precision oncology. Speaking today at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco, California, Illumina CEO, Francis deSouza, announced a series of oncology partnerships that aim to expan
   Global Genomic Biomarkers Market Trends, Growth, Size, Segmentation, Future Demands, Latest Innovation 2020-2026|| Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc, Eurofins Scientific, QIAGEN  2021/01/07 09:11:09 OpenPR
This Genomic Biomarkers concerning the Genomic Biomarkers market has been published to assist the user in understanding the market as a whole, its definitions, segmentation, market potential, influential trends, and the barriers that it is facing currently. The report covers
   Global Genetic Testing Market Outlook to 2022 Featuring Abbott Laboratories, Roche Diagnostics, Myriad Genetics, Thermo Fisher Scientific, Hologic, Cepheid, Agilent Technologies, and QIAGEN  2020/12/16 14:00:00 PR Newswire
DUBLIN, Dec. 16, 2020 /PRNewswire/ -- The "Global Genetic Testing Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering. "Global Genetic Testing Market Outlook 2022" provides a detailed analysis of the genetic testing market. The report also provides insight…
   Dec 15, 2020 – Glenview Capital Administration Buys Myriad Genetics Inc, Medtronic PLC, Amgen Inc, Sells Nuance Communicat  2020/12/16 05:37:30 Fintech Zoom
Dec 15, 2020 - Glenview Capital Administration Buys Myriad Genetics Inc, Medtronic PLC, Amgen Inc, Sells Nuance Communications Inc, ViacomCBS Inc, HCA Healthcare Inc -
   Genetic Testing Market 2020 Global Exclusive Analysis by Leading Players Overview | Abbott Laboratories, Bio-Rad Laboratories, Inc., Illumina Inc., Myriad Genetics, Inc., PerkinElmer Inc., QIAGEN N. V., Quest Diagnostics Incorporated  2020/12/15 13:26:58 OpenPR
Market Synopsis of Global Genetic testing Market: Genetic Testing Market is expected to grow at CAGR of 11.50% to reach USD 22834.19 million till 2024, revealed by Market Research Future (MRFR) with Global Genetic Testing Market Analysis by by Type, Method,
   Global Clinical Oncology Next Generation Sequencing Market Vigorous Growth 2020-2027 | Top Companies-F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., Thermo Fisher Scientific, Myriad Genetics Inc., BGI, Perkin Elmer, Inc  2020/12/10 15:45:51 OpenPR
“Global Clinical Oncology Next Generation Sequencing Market- Industry Trends and Forecast to 2027” Worldwide Industry Size, Offer and trends analysis during Period. Clinical Oncology Next Generation Sequencing Market report is a thoughtful analysis of the market presenting the propelled situation
   Preventive Healthcare Technologies And Services Market With Covid 19 Impact Analysis | Key Players: Omnicell Inc., Merck & Co. Inc., McKesson Corporation, GlaxoSmithKline plc., Medtronic, Quest Diagnostics Inc., Alere, Myriad Genetics Inc.  2020/12/09 07:13:12 OpenPR
The Preventive Healthcare Technologies And Services Market (2020) research report explores the market in terms of Revenue And Emerging Market Trends and Drivers and includes an up to date analysis and forecasts for various market segments, major players, and all

 関連キーワード  (先端医療機器_テクノロジ― 米国株 ミリアド・ジェネティックス MYGN Myriad Genetics Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)